A Study to Evaluate the Effect of Probiotic Supplement on Quality of Life

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

A Prospective, Randomized, Double-blinded, Placebo-controlled Study Evaluating the Safety and Impact of resB® Lung Support on Quality of Life in Adult Volunteers With Chronic Obstructive Pulmonary Disease or Non-cystic Fibrosis Bronchiectasis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05523180
• Other study ID #: R01-21-02-T0027
• Status: Active, not recruiting
• Phase: N/A
• Start date: September 1, 2022
• Est. completion date: September 2023

Study information

• Verified date: August 2023
• Source: ResBiotic Nutrition, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluate the impact of a specific oral probiotic blend on the quality of life of adults with respiratory conditions.

Description:

An imbalance and reduction of microbial diversity in the lung microbiota may negatively impact an individual's general health and quality of life. Further, individuals with respiratory conditions may take medications that may alter gut microbiome, which can have a negative impact on outcomes and quality of life. Evidence has emerged that there are interactions between gut and lung microbiomes, demonstrating the opportunity of using oral probiotics to support a healthy gut and/or lung microbiome, and subsequently, the general health and quality of life in this population.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 37
• Est. completion date: September 2023
• Est. primary completion date: August 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Adult participants who are 18-80 years of age (inclusive).

2. Have been diagnosed with chronic obstructive pulmonary disease or non-cystic fibrosis bronchiectasis and have been on a stable treatment regimen for = 6 months at screening.

3. Have a body mass index between 18.0-34.9 kg/m2 (inclusive).

4. Have normal or acceptable to the investigator vital signs (blood pressure, respiratory rate, heart rate) and normal or acceptable to the investigator physical exam findings (if applicable) at screening.

5. Individuals of childbearing potential must agree to practice a medically acceptable form of birth control for a certain time frame prior to the first dose of study

product and throughout the study, including:

1. use for at least 3 months prior to the first dose of study product: hormonal contraceptives including oral contraceptives, hormone birth control patch (e.g., Ortho Evra), vaginal contraceptive ring (e.g., NuvaRing), injectable contraceptives (e.g., Depo-Provera, Lunelle), or hormone implant (e.g., Norplant System)

2. use for at least 1 month prior to the first dose of study product: double-barrier method, intrauterine devices, or complete abstinence from sexual intercourse that can result in pregnancy

3. vasectomy of partner at least 6 months prior to the first dose of study product Individuals with potential to impregnate others must agree to use condom or other medically acceptable methods to prevent pregnancy throughout the study. Complete abstinence from sexual intercourse that can result in pregnancy is also acceptable.

6. Agree to refrain from treatments listed in the protocol in the defined timeframe.

7. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures.

Exclusion Criteria:

1. Participant has a history of heart disease, uncontrolled high blood pressure (i.e., =160 mmHg systolic or =100 mmHg diastolic), renal or hepatic impairment/disease, or uncontrolled diabetes (Type I or Type II) defined as not taking a stable dose of diabetes mellitus medication on the current regimen for a minimum of three months.

2. Participants on oxygen therapy.

3. Received a vaccine for COVID-19 in the 2 weeks prior to screening or during the study period, current COVID-19 infections, or currently have the post COVID-19 condition as defined by World Health Organization (WHO) (i.e., individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis).

4. Participant has a history of unstable thyroid disease, immune disorders and/or immunocompromised (e.g. HIV/AIDS), a history of cancer (except localized skin cancer without metastases or in situ cervical cancer) within 5 years prior to screening visit.

5. Major surgery in 3 months prior to screening or planned major surgery during the course of the study.

6. Participant has consumed probiotic supplements and is unwilling to stop at least one week prior to screening and throughout the study. Supplemental probiotics may include standalone probiotic supplements, vitamins with probiotics, and any foods supplemented with probiotics.

7. Participant is currently being prescribed antibiotics or states that they have been prescribed antibiotics within the 3 months prior to screening.

8. Participant has consumed supplemental enzymes and are unwilling to stop at least one week prior to screening and throughout the study. Supplemental enzymes may include standalone enzyme supplements, probiotic supplements with enzymes, and any medications containing enzymes.

9. Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g. dysphagia) and digestion (e.g. known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis).

10. Participants who are lactating, pregnant or planning to become pregnant during the study.

11. Have a known sensitivity, intolerability, or allergy to any of the study products or their excipients, or any of the rescue medications.

12. Receipt or use of an investigational product in another research study within 28 days prior to baseline visit.

Related Conditions & MeSH terms

• Bronchiectasis
• Chronic Obstructive Pulmonary Disease
• Fibrosis
• Lung Diseases
• Lung Diseases, Obstructive
• Non-cystic Fibrosis Bronchiectasis
• Pulmonary Disease, Chronic Obstructive

Intervention

Dietary Supplement:
• Probiotic
Active ingredients: Lactobacillus plantarum RSB11, 5 Billion colony forming units (CFU) Lactobacillus acidophilus RSB12, 5 Billion CFU Lactobacillus rhamnosus RSB13, 5 Billion CFU Holy basil leaf extract, 42.0 mg Turmeric root extract, 30.0 mg Vasaka leaf extract, 48.0 mg Inactive ingredients: Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide

Other:
• Placebo
Active ingredients: N/A Inactive ingredients: Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide

Locations

Country	Name	City	State
United States	Coral Research Clinic Corp.	Miami	Florida
United States	Premier Medical Associates	The Villages	Florida

Sponsors (2)

Lead Sponsor	Collaborator
ResBiotic Nutrition, Inc.	Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the effect of resB® Lung Support on quality of life	Change from baseline in St. George's Respiratory Questionnaire. The total score summarizes the impact of the condition on overall health status where 100 indicates the worst possible health status and 0 indicates best possible health status	12 weeks
Secondary	To determine the effect of resB® Lung Support on lung microbiome	Change from baseline in gut microbiome as assessed by 16S rRNA analysis from sputum samples	12 weeks
Secondary	To determine the effect of resB® Lung Support on gut microbiome	Change from baseline in gut microbiome as assessed by 16S rRNA analysis from fecal samples	12 weeks
Secondary	To determine the effect of resB® Lung Support on serum short-chain fatty acids	Change from baseline in serum short-chain fatty acids	12 weeks
Secondary	To determine the effect of resB® Lung Support on stool short-chain fatty acids	Change from baseline in stool	12 weeks
Secondary	To determine the effect of resB® Lung Support on biomarkers of inflammation	Change from baseline in serum concentration of metalloproteinase 9	12 weeks
Secondary	To determine the effect of resB® Lung Support on biomarkers of inflammation	Change from baseline in serum concentration of tripeptide N-acetyl proline-glycine-proline	12 weeks
Secondary	To determine the effect of resB® Lung Support on biomarkers of inflammation	Change from baseline in serum concentration of high-sensitivity C-reactive protein	12 weeks
Secondary	To determine the effect of resB® Lung Support on biomarkers of inflammation	Change from baseline in serum concentration of pro-inflammatory cytokines	12 weeks
Secondary	To assess the safety and tolerability of resB® Lung Support in adult participants with chronic obstructive pulmonary disease or non-cystic fibrosis bronchiectasis	Heart rate measurement	12 weeks
Secondary	To assess the safety and tolerability of resB® Lung Support in adult participants with chronic obstructive pulmonary disease or non-cystic fibrosis bronchiectasis	Blood pressure measurement	12 weeks
Secondary	To assess the safety and tolerability of resB® Lung Support in adult participants with chronic obstructive pulmonary disease or non-cystic fibrosis bronchiectasis	Respiratory rate measurement	12 weeks
Secondary	To assess the safety and tolerability of resB® Lung Support in adult participants with chronic obstructive pulmonary disease or non-cystic fibrosis bronchiectasis	Weight measurement	12 weeks
Secondary	To assess the safety and tolerability of resB® Lung Support in adult participants with chronic obstructive pulmonary disease or non-cystic fibrosis bronchiectasis	Body mass index measurement	12 weeks
Secondary	Change in Hemoglobin levels after taking resB® Lung Support	Change in Hemoglobin levels after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Mean Corpuscular Hemoglobin Concentration (MCHC) after taking resB® Lung Support	Change in Mean Corpuscular Hemoglobin Concentration (MCHC) after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Albumin after taking resB® Lung Support	Change in Albumin after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Total Protein after taking resB® Lung Support	Change in Total Protein after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Globulin after taking resB® Lung Support	Change in Globulin after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Reb Blood Cell (RBC) count after taking resB® Lung Support	Change in Reb Blood Cell (RBC) count after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in in Red Cell Distribution Width (RDW) after taking resB® Lung Support	Change in in Red Cell Distribution Width (RDW) after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) after taking resB® Lung Support	Change in Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Mean Corpuscular Hemoglobin (MCH) after taking resB® Lung Support	Change in Mean Corpuscular Hemoglobin (MCH) after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Platelet count after taking resB® Lung Support	Change in Platelet count after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in White Blood Cell (WBC) count after taking resB® Lung Support	Change in White Blood Cell (WBC) count after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in White Blood Cell (WBC) differential after taking resB® Lung Support	Change in White Blood Cell (WBC) differential after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Urea after taking resB® Lung Support	Change in Urea after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Sodium after taking resB® Lung Support	Change in Sodium after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Potassium after taking resB® Lung Support	Change in Potassium after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Chloride after taking resB® Lung Support	Change in Chloride after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Creatinine after taking resB® Lung Support	Change in Creatinine after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Bilirubin-total after taking resB® Lung Support	Change in Bilirubin-total after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Alkaline Phosphatase after taking resB® Lung Support	Change in Alkaline Phosphatase after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Aspartate Aminotransferase (AST) after taking resB® Lung Support	Change in Aspartate Aminotransferase (AST) after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Alanine Aminotransferase (ALT) after taking resB® Lung Support	Change in Alanine Aminotransferase (ALT) after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Change in Estimated Glomerular Filtration Rate (eGFR) after taking resB® Lung Support	Change in Estimated Glomerular Filtration Rate (eGFR) after taking resB® Lung Support compared to baseline	12 weeks
Secondary	Safety- participants experiencing adverse events	The number of participants experiencing Treatment Emergent Adverse Events (TEAEs)	12 weeks
Secondary	Safety- adverse events	The total number Treatment Emergent Adverse Events (TEAEs)	12 weeks